Circulating Mitochondrial DNA Content Associated with the Risk of Liver Cirrhosis: A Nested Case–Control Study

Wang, Chun; Hann, Hie‐Won; Hann, Richard S.; Wan, Shaogui; Myers, Ronald E.; Ye, Zhong; Xing, Jinliang; Yang, Hushan

doi:10.1007/s10620-015-3523-1

Cited by 14 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The alteration of mtDNA content can profoundly impair oxidative phosphorylation, calcium‐dependent stress signaling, adaptive metabolic responses, and innate immune system . A decrease level of mtDNA content has been documented in cirrhosis and HCC . The chronic HBV infection is an early stage of cirrhosis and HCC.…”

Section: Discussionmentioning

confidence: 99%

“…13 A decrease level of mtDNA content has been documented in cirrhosis and HCC. 9,10 The chronic HBV infection is an early stage of cirrhosis and HCC. However, unlike in cirrhosis and HCC patients, it's reported that HBV patients receiving nucleos(t)ide analogs (NAs) have higher levels of mtDNA content compared to healthy controls.…”

Section: Discussionmentioning

confidence: 99%

“…In a previous study, it was found that HBV‐related HCC had a significantly lower mtDNA content than healthy controls in PBL samples from a Chinese Han population . Similary, cirrhotic HBV patients had significantly lower mtDNA content than non‐cirrhotic HBV controls . Compared to patients with high mtDNA content, those with lower mtDNA content had a significantly increased risk of HCC or cirrhosis, suggesting that mtDNA content, mainly injured by ROS, might play an important role in HBV‐related diseases …”

Section: Introductionmentioning

confidence: 90%

“…HBV controls. 10 Compared to patients with high mtDNA content, those with lower mtDNA content had a significantly increased risk of HCC or cirrhosis, suggesting that mtDNA content, mainly injured by ROS, might play an important role in HBV-related diseases. 9,10 Inconsistently, compared to healthy controls, it's reported that HBV patients receiving nucleostide analogues (NAs) had higher mtDNA content which needs more researches to prove.…”

mentioning

confidence: 99%

“…10 Compared to patients with high mtDNA content, those with lower mtDNA content had a significantly increased risk of HCC or cirrhosis, suggesting that mtDNA content, mainly injured by ROS, might play an important role in HBV-related diseases. 9,10 Inconsistently, compared to healthy controls, it's reported that HBV patients receiving nucleostide analogues (NAs) had higher mtDNA content which needs more researches to prove. 11 Whatever, there have been few researches studying the mtDNA content alterations in CHB patients with or without antivirus therapy, therefore, it's meaningful to explore what the role of mtDNA content is in CHB and whether mtDNA content could be regarded as a disease maker in CHB.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Association between mitochondrial DNA content and baseline serum levels of HBsAg in chronic hepatitis B infection

et al. 2017

View full text Add to dashboard Cite

Recent studies have demonstrated a potential link between mitochondrial DNA (mtDNA) content and cirrhosis or hepatocellular carcinoma (HCC). However, there are few studies evaluating mtDNA content as a noninvasive marker of chronic hepatitis B infection (CHB). In this study, we conducted a case-control study to determine mtDNA content in peripheral blood leukocyte (PBL) samples from 76 CHB cases naïve to antivirus therapy and 96 healthy controls, and then evaluated the association between mtDNA content and baseline serum concentration of HBV markers. Consequently, CHB cases had significantly higher mtDNA content than healthy controls (1052.85 vs 618.98, P < 0.001). Pearson's correlation analysis revealed that mtDNA content was negatively correlated with the baseline levels of hepatitis B surface antigen (HBsAg) (r = -0.291, P = 0.011) in CHB patients. In a trend analysis, a statistically significant association was detected between lower mtDNA content and increasing levels of HBsAg (P = 0.015). In conclusion, our study provides the first epidemiological evidence that mtDNA content of CHB cases naive to antivirus therapy is significantly higher than healthy controls and the levels of mtDNA content is negatively associated with HBsAg. mtDNA content may serve as a potential noninvasive biomarker of CHB which may need more researches to validate.

show abstract

Section: Discussionmentioning

confidence: 99%